Abstract
Objectives To determine the association between frailty and medication-related harm requiring healthcare utilisation.
Design Prospective observational cohort study.
Setting 6 primary and 5 secondary care sites across South East England, September 2013 – November 2015.
Participants 1280 participants, 65 years old or over, who were due for discharge from general medicine and older persons’ wards following an acute episode of care. Exclusion criteria were limited life expectancy, transfer to another hospital and consent not gained.
Main outcome measures Medication-related harm requiring healthcare utilisation, including adverse drug reactions, non-adherence and medication error determined via triangulation of: patient/carer reports gathered through a structured telephone interview; primary care medical record review; and prospective consultant-led review of re-admission to recruiting hospital. Frailty was measured using a Frailty Index, developed using a standardised approach. Marginal estimates were obtained from logistic regression models to examine how probabilities of healthcare service use due to medication-related harm were associated with increasing polypharmacy and frailty.
Results Healthcare utilisation due to medication-related harm was significantly associated with frailty (OR = 10.06, 95% CI 2.06 to 49.26, p = 0.004), independent of age, gender, and polypharmacy. With increasing polypharmacy, the need for healthcare use as a result of MRH increases from a probability of around 0.2 to 0.4. This is also the case for frailty.
Conclusions Frailty is as important as polypharmacy in its association with MRH. Reducing the burden of frailty through an integrated health and social care approach, alongside strategies to reduce inappropriate polypharmacy, may reduce MRH related healthcare utilisation.
Trial registration Approved by the National Research Ethics Service, East of England (REC Reference 13/EE/0075)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-016-0191-8
Funding Statement
NIHR Research for Patient Benefit (PB-PG-0711-25094) and Guys and St. Thomas Charity (G100716).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PRIME study was approved by the National Research Ethics Service, East of England (REC Reference 13/EE/0075)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data relevant to the study are included in the article or uploaded as supplementary information. Further relevant anonymised patient level data is available on reasonable request.
